🚨 Major SCLC results at #ESMO26!
Phase III DeLLphi-305 (N=563): tarlatamab + durvalumab vs durvalumab 1L maintenance in ES-SCLC.
Median OS: 21.1 vs 12.7 mo
HR 0.42 (95% CI 0.32–0.54)
12-mo OS: 79.4% vs 53.3%
An important survival advance. #LCSM
178 views · 9 likes · 4 reposts · 3 replies
Tarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial
https://esmocongress.esmo.org- gilberto lopes@GlopesMd
@SclcSMASHERS @FDA @LUNGevity @lungoncdoc @StephenVLiu @HHorinouchi @g_mountzios @sands_jacob @LauraAlderMD @oncodaily @OncoAlert @Latinamd @LuisPaz_Ares @RManochakian @LuisRaezMD @triparnasen @LaurenByersMD @LungCancerEu @alissajcooper @BZhangMD @NaglaAKarimMD @Annechiangmd @IASLC @NCCN @ASCO #ESMO26 @larvol @tribeMDUS @sylvestercancer @oncbrothers @chinmay @Jani_Chinmay @colazagasti @openmedicineHQ @myesmo @openmedkate @openmedben @chadinabhan @YoungLungCancer @OncodailyLung @ClinicalLung #LCSM @LungPolicy @dan_morgxen @LAGurwitch
- gilberto lopes@GlopesMd
@SclcSMASHERS @FDA @LUNGevity @lungoncdoc @StephenVLiu @HHorinouchi @g_mountzios @sands_jacob @LauraAlderMD @oncodaily @OncoAlert @Latinamd @LuisPaz_Ares @RManochakian @LuisRaezMD @triparnasen @LaurenByersMD @LungCancerEu @alissajcooper @BZhangMD @NaglaAKarimMD @Annechiangmd @IASLC @NCCN @ASCO #ESMO26 @larvol @tribeMDUS @sylvestercancer @oncbrothers @chinmay @Jani_Chinmay @colazagasti @openmedicineHQ @myesmo @openmedkate @openmedben @chadinabhan @YoungLungCancer @OncodailyLung @ClinicalLung #LCSM @LungPolicy @dan_morgxen @LAGurwitch
- gilberto lopes@GlopesMd
PFS: 7.4 vs 1.9 mo (HR 0.34) ORR: 26.4% vs 4.1% Safety: • Grade ≥3 TEAEs: 46.8% vs 40.6% • CRS: 49.6% vs 1.4% (grade ≥3: 0.4% vs 0) • ICANS: 1.1% vs 0; none grade ≥3 Next: sequencing, biomarkers, CNS outcomes, QoL & access. Sands et al. LBA3.
Source: gilberto lopes · x.com